These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17162713)

  • 21. Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer.
    de Souza Sales JF; Cabello C; Alvarenga M; Torresan RZ; Duarte GM
    Breast; 2007 Apr; 16(2):197-203. PubMed ID: 17178225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century.
    Singh MN; Martin-Hirsch PL; Martin FL
    Med Sci Monit; 2008 Sep; 14(9):RA144-8. PubMed ID: 18758431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mastalgia treatment with tamoxifen].
    Ortíz-Mendoza CM; Lucas Flores MA; Domville Ede G
    Ginecol Obstet Mex; 2003 Oct; 71():502-7. PubMed ID: 15002689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ
    Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.
    Sonpavde G; Okuno N; Weiss H; Yu J; Shen SS; Younes M; Jian W; Lerner SP; Smith CL
    Urology; 2007 Jun; 69(6):1221-6. PubMed ID: 17572228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrauterine pressure changes during dysmenorrhea therapy.
    Smith RP; Powell JR
    Am J Obstet Gynecol; 1982 Jun; 143(3):286-92. PubMed ID: 6805330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary dysmenorrhea: current concepts.
    Jay MS; Taylor W
    Am Fam Physician; 1981 Nov; 24(5):129-34. PubMed ID: 7197460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interrelation of analgesia and uterine activity in women with primary dysmenorrhea. A preliminary report.
    Smith RP; Heltzel JA
    J Reprod Med; 1991 Apr; 36(4):260-4. PubMed ID: 2072357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
    Seo JH; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A first-in-human study of PDC31 (prostaglandin F2α receptor inhibitor) in primary dysmenorrhea.
    Böttcher B; Laterza RM; Wildt L; Seufert RJ; Buhling KJ; Singer CF; Hill W; Griffin P; Jilma B; Schulz M; Smith RP
    Hum Reprod; 2014 Nov; 29(11):2465-73. PubMed ID: 25164021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
    Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
    Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Adjuvant treatment of breast cancer. Endocrine therapy].
    Mouridsen HT; Andersen J
    Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
    Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
    Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective estrogen receptor modulators: an update on recent clinical findings.
    Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
    Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women.
    Furlanut M; Franceschi L; Pasqual E; Bacchetti S; Poz D; Giorda G; Cagol P
    Ther Drug Monit; 2007 Jun; 29(3):349-52. PubMed ID: 17529893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.